[go: up one dir, main page]

SMT201500069B - Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide - Google Patents

Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide

Info

Publication number
SMT201500069B
SMT201500069B SM201500069T SM201500069T SMT201500069B SM T201500069 B SMT201500069 B SM T201500069B SM 201500069 T SM201500069 T SM 201500069T SM 201500069 T SM201500069 T SM 201500069T SM T201500069 B SMT201500069 B SM T201500069B
Authority
SM
San Marino
Prior art keywords
fluorophenyl
carbossammide
dihydropyridin
chloropyridin
yloxy
Prior art date
Application number
SM201500069T
Other languages
English (en)
Inventor
Victor W Rosso
Gretchen Schroeder
Dilbir S Bindra
Madhushree Yeshwant Gokhale
Cletus John Nunes
Ajit B Thakur
Xiaotian Yin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT201500069B publication Critical patent/SMT201500069B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500069T 2010-04-30 2015-03-18 Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide SMT201500069B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32971010P 2010-04-30 2010-04-30
PCT/US2011/034417 WO2011137274A1 (en) 2010-04-30 2011-04-29 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide

Publications (1)

Publication Number Publication Date
SMT201500069B true SMT201500069B (it) 2015-05-05

Family

ID=44209564

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500069T SMT201500069B (it) 2010-04-30 2015-03-18 Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide

Country Status (17)

Country Link
US (2) US8911785B2 (it)
EP (1) EP2563763B1 (it)
JP (1) JP5820874B2 (it)
KR (1) KR101897302B1 (it)
CN (1) CN102971296B (it)
DK (1) DK2563763T3 (it)
ES (1) ES2533075T3 (it)
HR (1) HRP20150105T1 (it)
MY (1) MY183769A (it)
PH (1) PH12012502019A1 (it)
PL (1) PL2563763T3 (it)
PT (1) PT2563763E (it)
RS (1) RS53790B1 (it)
SG (1) SG184891A1 (it)
SI (1) SI2563763T1 (it)
SM (1) SMT201500069B (it)
WO (1) WO2011137274A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096858A1 (en) 2011-12-22 2013-06-27 Life Technologies Corporation Cell culture media and methods
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
EP3911320A4 (en) * 2019-01-15 2022-11-30 The Translational Genomics Research Institute PHOSPHONATE CONJUGATES AND THEIR USES
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
TR200504775A1 (tr) 2005-11-30 2007-10-22 Esen Beki̇r Kendinden metal takviyeli pvc pencere ve kapı profilleri
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
WO2008058229A1 (en) * 2006-11-08 2008-05-15 Bristol-Myers Squibb Company Pyridinone compounds
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 4−ピリジノン化合物および癌についてのその使用

Also Published As

Publication number Publication date
PH12012502019A1 (en) 2017-08-18
SI2563763T1 (sl) 2015-03-31
MY183769A (en) 2021-03-12
WO2011137274A1 (en) 2011-11-03
PT2563763E (pt) 2015-03-31
AU2011245269A1 (en) 2012-12-20
SG184891A1 (en) 2012-11-29
US9233948B2 (en) 2016-01-12
ES2533075T3 (es) 2015-04-07
CN102971296A (zh) 2013-03-13
EP2563763A1 (en) 2013-03-06
RS53790B1 (sr) 2015-06-30
KR20130100237A (ko) 2013-09-10
US20130039989A1 (en) 2013-02-14
CN102971296B (zh) 2015-11-25
HK1179260A1 (en) 2013-09-27
EP2563763B1 (en) 2014-12-31
US8911785B2 (en) 2014-12-16
PL2563763T3 (pl) 2015-06-30
US20150065719A1 (en) 2015-03-05
HRP20150105T1 (hr) 2015-03-13
JP5820874B2 (ja) 2015-11-24
JP2013525455A (ja) 2013-06-20
DK2563763T3 (en) 2015-04-07
KR101897302B1 (ko) 2018-09-11

Similar Documents

Publication Publication Date Title
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
BR112015002738A2 (pt) composto , e , composição farmacêutica
SMT201600350B (it) Composizioni farmaceutiche
SMT201700008B (it) Composizione farmaceutica
EP2616024A4 (en) BALANCED PHAKOEMULSIFICATION TIP
BR112013024267A2 (pt) compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
LT3202460T (lt) Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
LT2694484T (lt) Pirimidino dariniai, skirti virusinių infekcijų gydymui
DK3246018T3 (da) Farmaceutisk sammensætning
DK3685835T3 (da) Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014003052A2 (pt) composições farmacêuticas
LT3702351T (lt) Kompozicijos, apimančios mek inhibitorių
CO6930367A2 (es) Composiciones farmaceúticas
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
EE201300005A (et) Ravimkoostis
DK2938194T3 (da) N-(substituerede)-5-fluor-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidin-1 (2h)-carboxylatderivater
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
HUE040370T2 (hu) Gyógyszerkészítmények
CO6801722A2 (es) Composiciones farmacéuticas
IT1397694B1 (it) Puntale per attacchi da sci-alpinismo.
CL2014002034A1 (es) Compuestos derivados de isoxazol-fenil-azetidina fenil sustituidos; y compuestos intermediarios.
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
BR112014032501A2 (pt) composto, e, composição farmacêutica.